2.33
전일 마감가:
$2.24
열려 있는:
$2.295
하루 거래량:
356.78K
Relative Volume:
0.41
시가총액:
$247.95M
수익:
$45.44M
순이익/손실:
$-35.43M
주가수익비율:
-6.8529
EPS:
-0.34
순현금흐름:
$-25.39M
1주 성능:
+9.91%
1개월 성능:
+7.37%
6개월 성능:
-51.05%
1년 성능:
-49.13%
맥스사이트 Stock (MXCT) Company Profile
명칭
Maxcyte Inc
전화
301-517-5556
주소
9713 KEY WEST AVENUE,, ROCKVILLE
MXCT을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
MXCT
Maxcyte Inc
|
2.33 | 238.15M | 45.44M | -35.43M | -25.39M | -0.34 |
![]()
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
![]()
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
![]()
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
![]()
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
![]()
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
맥스사이트 Stock (MXCT) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-07-22 | 개시 | Stephens | Overweight |
2023-11-29 | 개시 | Craig Hallum | Buy |
2021-10-15 | 재개 | Cowen | Outperform |
2021-08-24 | 개시 | BTIG Research | Buy |
2021-08-24 | 개시 | Cowen | Outperform |
2021-08-24 | 개시 | Stephens | Overweight |
2021-08-24 | 개시 | Stifel | Buy |
2021-08-24 | 개시 | Wedbush | Outperform |
2021-08-24 | 개시 | William Blair | Outperform |
모두보기
맥스사이트 주식(MXCT)의 최신 뉴스
Published on: 2025-07-23 21:52:41 - Autocar Professional
What drives MaxCyte Inc. stock priceFree Technical Analysis Support - Autocar Professional
What analysts say about MaxCyte Inc. stockFree Real-Time Stock Data - Autocar Professional
MaxCyte Inc. Stock Analysis and ForecastHigh-yield capital appreciation - jammulinksnews.com
Is MaxCyte Inc. a good long term investmentPhenomenal capital appreciation - Autocar Professional
Why MaxCyte Inc. stock attracts strong analyst attentionHigh Potential Stock Ideas - Newser
What makes MaxCyte Inc. stock price move sharplySwing Trade Signals - Newser
IWN ETF Implied Analyst Target Price: $198.15 - AInvest
How MaxCyte Inc. stock performs during market volatilityDaily Swing Candidates - Newser
MaxCyte to Report Second Quarter 2025 Financial Results on August 6, 2025 - The Manila Times
MaxCyte, Inc. to Release Second Quarter 2025 Financial Results on August 6th - Nasdaq
PHC announces exclusive distribution of MaxCyte ExPERT platform in Japan - BioSpectrum Asia
PHC TO EXCLUSIVELY DISTRIBUTE MAXCYTE CELL ENGINEERING PLATFORM IN JAPAN - bernama
Business Wire - JIJI PRESS
PHC Announces Exclusive Distribution of MaxCyte® ExPERT™ Platform in Japan - Business Wire
MaxCyte Cancels AIM Market Trading for Common Stock - TipRanks
MaxCyte shares trading for last time in London - Sharecast.com
Moving Gene Editing Advances Into the Clinic - the-scientist.com
MaxCyte stockholders approve AIM delisting, company to trade only on Nasdaq - Investing.com
MaxCyte Shareholders Approve Equity Plan Amendment - TipRanks
MaxCyte shareholders approve equity plan expansion, AIM delisting - Investing.com
Analyzing Ratios: MaxCyte Inc (MXCT)’s Financial Story Unveiled - DWinneX
MaxCyte shareholders approve equity plan expansion, AIM delisting By Investing.com - Investing.com UK
California State Teachers Retirement System Sells 82,134 Shares of MaxCyte, Inc. (NASDAQ:MXCT) - Defense World
MaxCyte Announces Change in Major Holdings by BlackRock - TipRanks
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing By Investing.com - Investing.com South Africa
MaxCyte & Ori Biotech Integrate Platforms for Efficient Manufacturing - Contract Pharma
Market news - investments.halifax.co.uk
MaxCyte enters collaboration with Ori Biotech - Sharecast.com
MaxCyte (MXCT) Partners with Ori Biotech to Boost Cell Therapy Manufacturing | MXCT Stock News - GuruFocus
MaxCyte and Ori Biotech partner to enhance cell therapy manufacturing - Investing.com Australia
맥스사이트 (MXCT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):